Hereditary breast and ovarian cancer: review and future perspectives.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesA prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group studyA high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumorsInvestigational agents in development for the treatment of ovarian cancerEnhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.Development of serous ovarian cancer is associated with the expression of homologous recombination pathway proteins.Genetic predisposition, parity, age at first childbirth and risk for breast cancer.Association of COMT Val158Met polymorphism and breast cancer risk: an updated meta-analysisReligiosity, spirituality, and psychological distress in African-Americans at risk for having a hereditary cancer predisposing gene mutation.Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma.Quantitative assessment of the association between rs2046210 at 6q25.1 and breast cancer riskGenetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP Beta promoter by an NRF-1-containing complexComparison of endoscopic and clinical characteristics of patients with familial and sporadic Barrett's esophagus.Cancer worry among Norwegian male BRCA1/2 mutation carriers.Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repairCancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer.Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.Preoperative Systemic Treatment in BRCA-Positive Breast Cancer Patients: Case Report and Review of the Literature.A Novel Scheme for Optimal Control of a Nonlinear Delay Differential Equations Model to Determine Effective and Optimal Administrating Chemotherapy Agents in Breast CancerBRCA1 185delAG Mutation Enhances Interleukin-1β Expression in Ovarian Surface Epithelial Cells.Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies.Impact of risk-reducing salpingo-oophorectomy in premenopausal women.No association between ovarian cancer susceptibility variants and breast cancer risk among Chinese women.Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.The impact of an interventional counselling procedure in families with a BRCA1/2 gene mutation: efficacy and safetyLoss of BRCA1 expression leads to worse survival in patients with gastric carcinomaA new rapid methodological strategy to assess BRCA mutational status.Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patientsBreast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality?Anti-cancer and Sensibilisation Effect of Triptolide on Human Epithelial Ovarian Cancer.Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implicationsBRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications.Awareness and attitude regarding reproductive options of persons carrying a BRCA mutation and their partners.Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia.Dissimilarity between sporadic, non-BRCA1/2 families and hereditary breast cancer, linked to BRCA genes, in the Tunisian population.Mutation spectrum and prevalence of BRCA1 and BRCA2 genes in patients with familial and early-onset breast/ovarian cancer from Tunisia.
P2860
Q21129302-8636F007-AC81-4AEB-AAEE-43E77750C2BEQ30431721-AF723862-9AC1-40CA-9989-B28A60EDEA85Q33575946-36752DFE-6C42-4842-A7BC-CE00319924D1Q33920800-C7321B9D-4495-4C90-8EA1-4FCCB1A14E06Q33965570-02986951-C655-47C7-BD0E-961EA2827FD1Q34253229-4ADE805B-8B75-474B-984E-6DC72C68557DQ34367710-092CDC97-209C-4299-909F-E197263EF3ADQ34435081-A85BBC9A-3C24-42A1-94DA-24102759765CQ34582236-A57C8705-C3F1-4E8E-B659-55B5AD25B5FAQ34626842-08D99957-F986-48C7-8FEE-2765FF71E951Q34778648-C506D4FF-910E-4444-B827-696CDAA33E80Q35022825-4871CEEF-23E6-4599-A7AE-59CE46DE0293Q35081354-C29ABCEF-E3F9-410C-B60D-33C8B6AB0BE3Q35129319-CBCF6F63-09C0-4D50-AD04-679041AC7463Q35219186-D912A7AA-6FEC-4EFC-8592-528BABD18C7EQ35251010-7FAF1959-6CD5-4F70-BB16-ECCE0589AF13Q35748787-DB04952A-DDE4-42B0-A2AC-127C6E2FD947Q35758403-1772AEB9-B3B3-42FE-980D-DC8C82729813Q35916613-0BCEE04B-FEE5-4331-9995-403DCEE360DCQ35976084-D8159652-413F-4FF2-A386-01D0BB41D235Q36000628-97EFF6E1-8898-4ECB-935C-811DFC90F532Q36017531-50209EA3-DE37-4B3E-AF36-863A130270DDQ36353571-051DDD0E-C896-412E-BA4D-3DB1324750F8Q36372962-6B90C7F7-5BB0-44BE-84D4-7C9BA3CBF681Q36680998-B0A44364-A532-4CE1-A4FF-E226472459FDQ36700472-63DBA0A6-BC84-4972-ACBF-1DF4F771D771Q36717832-874DF6F3-1A22-4C1E-9C75-EE30D0D689D7Q36731204-12540FD4-E197-4403-9E64-7103EC94E636Q36809380-2CDA6665-70F0-4C09-8060-687E555AD192Q36922384-D672B374-F95E-4405-800E-7FDC8C5D38B5Q37185861-6F7643E0-AE39-472B-9E5A-278E4A121681Q37308563-90B0DA67-F677-4953-B3D7-7635C032C6FEQ37397607-4DE67AD9-7AA5-46BC-B752-9395BAC710F8Q37427962-F05EDAD6-12B9-497F-8C0C-00406795DA3AQ37525906-56D6EBC5-1A78-455D-9F2C-66A5A1A659E5Q37770590-6D10D42A-72D5-420A-9E02-608FFE900648Q38772089-23245CE3-BA1C-4D08-83A4-ACFD25ABCB11Q38985539-42665690-C6E9-43FA-850F-FD0A034A822DQ39395803-8248D4C4-1426-4F83-B73D-E980199191BFQ39395809-34D45B18-A082-4E0C-90EB-8B6B5AB27084
P2860
Hereditary breast and ovarian cancer: review and future perspectives.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Hereditary breast and ovarian cancer: review and future perspectives.
@ast
Hereditary breast and ovarian cancer: review and future perspectives.
@en
type
label
Hereditary breast and ovarian cancer: review and future perspectives.
@ast
Hereditary breast and ovarian cancer: review and future perspectives.
@en
prefLabel
Hereditary breast and ovarian cancer: review and future perspectives.
@ast
Hereditary breast and ovarian cancer: review and future perspectives.
@en
P2860
P50
P1476
Hereditary breast and ovarian cancer: review and future perspectives.
@en
P2860
P2888
P356
10.1007/S00109-005-0696-7
P577
2005-11-11T00:00:00Z